[Benign cancers of the stomach: radiological and endoscopic correlation on ten cases (author's transl)].

The Authors refer to their experience on 10 cases of benign cancer of the stomach studied either radiologically or endoscopically before the surgery intervention. Moreover the authors emphasize the importance of the association between the radiological investigation and the fibroscope in the determination of the benign characters of the gastric neoplasm and the possibility given by the endoscope to effect an extemporaneous biopsy in the cases of uncertain interpretation.

[Target cimetidine treatment of peptic ulcer. Considerations and assessment of a new dosage].

32 patients suffering from peptic ulcer have been selected. Of these 12 formed part of a previous series treated with cimetidine and subsequently relapsed; the other 20 were selected on the basis of endoscopic and functional examinations and were treated for the first time with cimetidine. The drug doses used were 1.

Endoscopic study of the gastro-intestinal tolerance of glucamethacin.

A gastroscopic study was carried out in patients with rheumatic disorders to investigate the gastric tolerance of glucamethacin, a new, non-steroidal anti-inflammatory agent. The first stage was a double-blind crossover comparison of the effects of glucamethacin (420 mg/day) and indomethacin (100 mg/day), each given for 15 days in random order to 30 patients. In the second, open stage, 70 such patients, most of whom also had gastrointestinal pathology, received glucamethacin (420 mg/day) for 25 days.

[Endoscopic study on the gastric tolerance of antalgic-antirheumatic substances:parsalmide].

The gastric tolerance of parsalmide, a new analgesic, antirheumatic and sedative substance was tested on a group of 50 arthrorheumatic patients with the purpose of assessing gastric damage if any. It was also compared with the tolerance of the better known antitrheumatic drugs in current use. The study was conducted with the endoscopic method, parsalmide being administered in quantities of 600 mg/die per os, broken up into 3 doses, for a period of 20 days.